Pulmonary fibrosis is characterized by a loss of lung epithelial cells, replaced by interstitial myofibroblasts to deposit extracellular matrix (ECM) proteins. Previous studies demonstrated that hepatocyte growth factor (HGF) improved lung fibrosis in murine models, whereas molecular mechanisms whereby HGF improved lung fibrosis have yet to be fully understood. When MRC-5 human lung fibroblasts were treated with transforming growth factor-β1, the cells underwent phenotypic change similar to myofibroblasts and this was associated with upregulation of c-Met/HGF receptor expression. For the myofibroblast-like cells, HGF increased activities of MMP-2/-9, predominant enzymes for breakdown of fibronectin (FN). Under such conditions, HGF induced caspase-dependent apoptosis, linked with a decrease in a FN central cell binding (CCB) domain involved in FAK phosphorylation. When MMI270 (a broad-spectrum MMP inhibitor) was added together with HGF, decreases in FN-CCB domain expression and FAK phosphorylation by HGF were restored, and these events were associated with an inhibition of HGF-induced apoptosis, suggesting that increased activities of MMPs underlie the major mechanism of HGF-mediated apoptosis in myofibroblasts. In bleomycin-treated mice, c-Met expression was found on interstitial myofibroblasts and HGF increased apoptosis in culture of myofibroblasts isolated from bleomycin-treated murine lungs. Furthermore, administration of recombinant HGF to bleomycin-treated mice increased lung MMP activities and enhanced myofibroblast apoptosis, while in vivo MMI270 injections together with HGF inhibited such MMP activation, leading to suppressed myofibroblast apoptosis. In conclusion, we identified HGF as a key ligand to elicit myofibroblast apoptosis and ECM degradation, whereas activation of the HGF/c-Met system in fibrotic lungs may be considered a target to attenuate progression of chronic lung disorders. ersistent injuries in lung tissues (such as chronic infections, antitumor drugs, and pulmonary hypertension) cause a progressive loss in alveolar epithelial components, the result being chronic respiratory failure (1). Although the number of chronic pulmonary diseases is now on the increase worldwide, there has been no effective treatment except for a lung graft transplantation (1). Chronic lung diseases are histologically defined as interstitial fibrosis, where extracellular matrix (ECM) proteins are overproduced to cover the loss in epithelial areas (1, 2). Such extensive ECM deposition limits a space for epithelial cells to regenerate, resulting in accelerated lung tissue damage and respiratory failure. In other words, an antifibrotic approach (including ECM degradation) may lead to morphological and functional repairs. Therefore, it is important to elucidate an intrinsic mechanism(s) whereby progression of lung fibrogenesis is controlled at a molecular level(s).
ersistent injuries in lung tissues (such as chronic infections, antitumor drugs, and pulmonary hypertension) cause a progressive loss in alveolar epithelial components, the result being chronic respiratory failure (1) . Although the number of chronic pulmonary diseases is now on the increase worldwide, there has been no effective treatment except for a lung graft transplantation (1) . Chronic lung diseases are histologically defined as interstitial fibrosis, where extracellular matrix (ECM) proteins are overproduced to cover the loss in epithelial areas (1, 2) . Such extensive ECM deposition limits a space for epithelial cells to regenerate, resulting in accelerated lung tissue damage and respiratory failure. In other words, an antifibrotic approach (including ECM degradation) may lead to morphological and functional repairs. Therefore, it is important to elucidate an intrinsic mechanism(s) whereby progression of lung fibrogenesis is controlled at a molecular level(s).
In chronically injured lungs, interstitial myofibroblasts play a central role in production of ECM proteins (such as collagen and fibronectin [FN] ) (2) . In this process, resident fibroblasts can be activated under transforming growth factor-β1 (TGF-β1)-mediated signalings and then myofibroblasts proliferate to compensate for a loss in pulmonary epithelial cells (3) (4) (5) . Actually, degrees of myofibroblast hyperplasia (i.e., myofibroblastosis) reflect well the prognosis of lung fibrosis (6, 7) . The fate of tissue fibrosis is in part regulated via a balance between myofibroblast survival vs. apoptosis (8) . For example, myofibroblast apoptosis becomes evident during progression of ECM disappearance (e.g., "resolution" of fibrosis) in liver cirrhosis (9) and kidney fibrosis (10) , suggesting a key role for myofibroblast removal to reverse tissue fibrosis. However, whether and how myofibroblast cell death occurs during resolution of pulmonary fibrosis remained to be addressed.
Hepatocyte growth factor (HGF) was identified and cloned as a mitogen for mature hepatocytes (11, 12) . There is now ample evidence that HGF plays an essential part in parenchymal repair and protection in various organs (13, 14) . In lungs, HGF is a potent regenerative and cytoprotective factor during organogenesis or in cases of acute injuries (15) (16) (17) (18) . Actually, early prevention of lung parenchymal destruction by HGF does not lead to subsequent fibrogenesis (19, 20) . However, resolution (rather than prevention) of tissue fibrosis is more important especially after manifestation of chronic respiratory dysfunctions. HGF is a potent inducer of ECM-degrading enzymes such as matrix metalloproteinases (MMPs) (13) , which are overexpressed during progression of myofibroblast apoptosis (9) . Thus, we hypothesize that HGF may have direct effects on interstitial myofibroblasts toward resolution from fibrotic changes of the lungs.
To test our hypothesis, we used mice and culture models of lung fibrosis and addressed 1) whether HGF targets and removes interstitial myofibroblasts when a sclerotic lesion is developed and 2) how myofibroblast apoptosis occurs along with disappearance of interstitial ECM proteins. We provide evidence that HGF targets interstitial myofibroblasts and induces MMPdependent apoptosis in a process of reducing pulmonary fibrosis, even under persistent lung injuries.
MATERIALS AND METHODS

Animals and HGF treatments
Based on a previous report (19) , 8-wk-old C57B/6 mice (SLC, Hamamatsu, Japan) were treated with bleomycin sulfate (BLM) (Nippon Kayaku, Kyoto, Japan) (5 mg/mouse/day, s.c.) for 4 serial weeks and used as an animal model of lung fibrosis. Two weeks after initiating the BLM injections, 12 mice were given recombinant human HGF (rh-HGF: 500 µg/kg/12 h, s.c.) for 1 or 2 wk and then killed to sample lung tissues. The remaining mice were given s.c. injections of an identical volume of saline. Likewise, normal C57B/6 mice were treated with saline or rh-HGF and used as basal control groups. To investigate the participation of MMP(s) in HGF-produced anti-fibrosis, we administrated MMI270 (300 µg/kg per 48 h, s.c.) (21) to HGF-treated BLM mice.
Histochemical examinations
After fixation with cold 70% ethanol or 10% formalin, lung tissues were embedded in paraffin and subjected to histochemical procedures (15) (16) (17) 22) . To detect interstitial fibrosis, goat IgG against rat type I collagen (Chemicon, Temecula, CA) was applied to formalin-fixed lung sections, followed by a second reaction with biotin-labeled anti-goat IgG (Vector, Burlingame, CA). An avidin-peroxidase coupling reaction was tested on the sections, using a kit (Vectstain Elite, Vector), and immunoreactive signals were visualized with 3-3′-diamino-benzidine (Vector). Interstitial myofibroblasts were detected using mouse IgG against α-smooth muscle actin (α-SMA) (DAKO, Glostrup, Denmark). The α-SMA-positive interstitial (but not peribronchial) areas of the total area were assessed using computer-aided image analysis (NIH image) of tissue sections. At least 20 fields at 200-fold magnification were captured and assessed in all the samples. Stromal cells were detected using anti-vimentin mouse IgG (DAKO) as a primary antibody. HGF receptor was detected using an anti-mouse c-Met rabbit IgG (SP-260; Santa Cruz Biotechnology, Santa Cruz, CA). To examine c-Met localization on (myo-)fibroblasts, we applied fluorescence techniques: c-Met and α-SMA (or vimentin) were visualized in the same tissue sections using an Alexa488-conjugated anti-rabbit IgG goat IgG (Molecular Probes, Eugene, OR) and an Alexa546-labeled anti-mouse IgG rabbit IgG (Molecular Probes), respectively.
Biochemical analyses
Lung active MMP levels were measured, using a fluorescence assay (MMP-1/MMP-9 kit: Yagai, Yamagata, Japan), as previously reported (22) . The lung tissue extract was obtained, according to the manufacturer's instructions. Furthermore, hydroxyproline levels were measured to quantify the degree of murine lung fibrosis, according to an established method (23) .
Cell culture
MRC5 cells were adjusted at a density of 3 × 10 4 cells/cm 2 (i.e., 80% confluence) and incubated at 38°C for 48 h in 0.1% fetal bovine serum (FBS)-supplemented α-MEM medium (Gibco, Grand Island, NY) with recombinant human TGF-β1 (10 ng/ml) (R&D Systems, Minneapolis, MN). After incubation with TGF-β1, lysates obtained from total cells (3×10 5 cells) were collected into lysis buffer (20 mM Tris-HCl/150 mM NaCl/10 mM EDTA/0.5% Triton X-100, pH 7.4) then subjected to SDS-PAGE, electrotransfer, and immunoblotting procedures (24) . Anti-α-SMA IgG and anti-human c-Met rabbit IgG (C-12, Santa Cruz Biotechnology) were used to determine c-Met expression on myofibroblasts. After reactions with peroxidase-labeled antibodies (DAKO), signals were visualized on PVDF membranes, using an ECL kit (Amersham-Pharmacia, Little Chalfont, UK). We next extracted mRNA from the MRC5 cells to detect changes in α-SMA and c-Met at transcription levels. Each mRNA was reversed to cDNA and subjected to amplification with the following primers specific to each cDNA (primer designs: α-SMA, 5′-CCC AGC CAA GCA CTG TCA-3′ vs. 5′-TCC AGA GTC CAG CAC GAT G-3′; and c-Met, 5′-GTT TCC CAA TTT CTG ACC-3′ vs. 5′-TAT ATC AAA GGT GTT ACG T-3′), and GAPDH was used as an internal control (5′-GGA TTT GGC CGT ATT GG-3′ vs. 5′-GGA TTT GGC CGT ATT GG-3′)
Detection of apoptosis
The TGF-β1-stimulated MRC5 cells were washed twice with medium and subjected to rh-HGF treatments (0, 10, 30, and 100 ng/ml) for 24, 48, and 96 h under FBS-free conditions. To test effects of rh-HGF on serum starvation-induced cell injury, we determined nuclear DNA fragmentation levels using an ELISA system (Cell Death Detection, Roche Diagnostic GmbH, Mannheim, Germany). The remaining myofibroblasts were incubated on a glass slip and fixed in cold 10% formalin. After the slip was washed, apoptosis was detected in the preparation, using a TUNEL kit (ApoTag TM , Intergen, Purchase, NY). Cells positive for TUNEL were counted in at least 200 myofibroblasts. To detect active caspase-3, we incubated the cell preparations with anti-caspase-3 rabbit IgG (Promega, Madison, WI), which was followed by the ABC method, as described. DEVD-FMK (Calbiochem, San Diego, CA) was used as a caspase inhibitor to determine the role of caspases in the apoptotic changes. Furthermore, intrinsic myofibroblasts were isolated from BLM-treated murine lungs, according to a previous report (25) . After expansion of the cells in a primary culture system, these cells were incubated with rh-HGF (100 ng/ml) for 96 h under FBS-free conditions and then subjected to TUNEL staining, as described.
Evaluation of ECM and MMPs
ECM and MMP levels were evaluated in TGF-β1-induced MRC5 cells. Effect of HGF on MMP-2/-9 levels in the supernatants were also evaluated, using a kit (BIOTRAK MMP-2/-9TM, Amersham). The remaining lysates were subjected to immunoblot analyses, as described above, using anti-human FN mouse IgG (Chemicon). We added an antibody specific to FN central cell binding (CCB) domain (E3E, Chemicon) into the MRC5 culture and examined the effects on apoptosis, based on TUNEL stainings, as mentioned. The FN-CCB accumulation levels were checked in myofibroblast cell lysates, using immunoblot analysis where anti-FN-CCB IgG (E2E) was used as a primary antibody. To detect FN-CCB in vivo, we applied E2E antibody on the lung tissue slices, which was followed by our peroxidase method.
MMP inhibition in culture
To determine roles of MMPs in the onset of the apoptosis, we used MMI270 as an MMP inhibitor. This drug is designed as a novel synthetic hydroxamic acid derivative able to competitively bind the Zn 2+ ion in the active site of a wide range of MMPs (21) . MMI270 (kindly donated by Dr. M. Nakajima, Novartis, Tsukuba, Japan) was added into the culture at an optimal concentration (2×10 -5 M). To establish a direct function of MMPs in apoptosis, we added recombinant human MMP-2/-9 (50 µM, Chemicon) to the culture system. The lung myofibroblasts were incubated for 96 h in the presence or absence of rh-HGF, and the effect of MMI270 or of MMPs was evaluated based on the TUNEL scores, as mentioned. For evidence of ECM-related signals, focal adhesion kinase (FAK) or its phosphorylated FAK in the lysates was examined. The samples were subjected to electrophoresis, transferred on PVDF membranes, and stained with anti-chicken FAK mouse IgG (BD Biosciences, San Jose, CA) or anti-FAK [pY397] rabbit IgG (Biosource, Camarillo, CA).
RESULTS
Improvements of lung fibrosis by HGF in BLM-treated mice
It is still unclear whether HGF reduces connective tissue areas during the progression of lung fibrogenesis. This being the case, we gave rh-HGF to BLM-treated mice for 2 wk after the progression of lung fibrosis (Fig. 1A) . Immunohistochemistry revealed that type I collagen was extensive in interstitial areas of the saline group, whereas the type I collagen deposition was much less extensive in the HGF-treated group (4W) (Fig. 1B, top ). There was an apparent decrease in collagen-stained interstitial areas of the HGF-treated group (4W) compared with those in the pretreatment (2W) or in saline (4W) groups. Likewise, lung hydroxyproline levels in saline-injected mice increased during the experimental periods, while rh-HGF treatment reduced the hydroxyproline levels (4W: saline, 67.5±12.8 µg/mg vs. HGF, 30.5±4.82 µg/mg, P<0.01) (Fig. 1B, bottom) . In an endpoint of the experiment (i.e., 4W), administration of HGF into the BLM-treated mice reduced the lung hydroxyprline levels near basal levels, thus suggesting >80% recovery from pulmonary fibrosis by HGF. Furthermore, little effect of HGF on normal lungs means a specific function of HGF in the diseased lung tissues. In this fibrosis-reduced process, accumulation of myofibroblasts (i.e., α-SMA-positive interstitial cells) became faint after HGF therapy, whereas myofibroblastosis became evident through 2-4 wk in control BLM mice (Fig. 1C) . In our experiments, injections of rh-HGF did not elicit production of endogenous antibodies capable of neutralizing human HGF (not shown), similar to previous cases (15, 17, 19, 22, 24) .
Changes in c-Met localization during progression of pulmonary fibrosis in mice
To determine whether HGF directly targets interstitial fibrotic areas, we checked c-Met localization in lung tissues. In lungs treated with BLM, c-Met was noted on not only parenchymal but also interstitial areas ( Fig. 2A, left) . In the fibrotic lung, α-SMA-positive signals were concentrated on interstitial areas ( Fig. 2A, middle) . Most of the α-SMA-stained cells were also immunopositive for c-Met ( Fig. 2A, right) . In contrast, c-Met was noted mainly on parenchymal regions in lungs of healthy mice (Fig. 2B, left) . In the normal lungs, c-Met was not overlayed on vimentin-positive interstitial cells (Fig. 2B) , which possibly included resting stromal cells. These findings suggest that the c-Met expression in lung fibroblasts is up-regulated during "activation" toward myofibroblast-like cells and activated myofibroblast-like cells are the potential target of HGF, similar to the case in glomerular mesangial cell activation (24) .
Induction of apoptosis in cultured myofibroblasts by HGF
Based on the finding that phenotypic activation of lung fibroblasts was associated with upregulation of c-Met expression, we next examined biological effects of HGF on myofibroblastlike cells. To address this notion, MRC5 human lung fibroblasts were used. When MRC5 cells were treated with TGF-β1 for 48 h, expression of α-SMA, as determined by Western blot, was remarkably increased (Fig. 3A) , suggesting that TGF-β1 facilitated phenotypic activation of MRC5 cells toward myofibroblast-like cells. Expression of type I collagen in MRC5 cells was also strongly increased by TGF-β1 (not shown). Importantly, phenotypic change of MRC5 cells by TGF-β1 was associated with up-regulation of c-Met expression (Fig. 3A, left) . Likewise, increases in expressions of α-SMA and c-Met by TGF-β1 treatment were seen in RT-PCR analysis (Fig. 3A, right) , suggesting that increases in α-SMA and c-Met expression by TGF-β1 might be attributable to transcriptional up-regulation. Taken together with the finding that c-Met was up-regulated in α-SMA-positive myofibroblast-like cells in vivo and that TGF-β1 is a key mediator in fibrotic change of the lung (3-5), MRC5 cells phenotypically changed to myofibroblast-like cells by pretreatment with TGF-β1 seemed to provide an appropriate model to address biological effects of HGF on lung myofibroblast-like cells.
To determine the function of c-Met, we added HGF to cultures of MRC5 cells pretreated with TGF-β1. The myofibroblast-like MRC5 cells strongly attached to a dish with spread processes, while HGF enhanced "detachment" of the cells for up to 96 h of the serum-free culture (Fig. 3B,  left) . In this process, DNA fragmentation levels were dose-dependently increased by HGF, following 48 h after addition of HGF (Fig. 3B, right) , meaning enhanced apoptotic cell death by HGF. Along with progression of DNA fragmentation, nuclear caspase-3-positive myofibroblasts increased especially 96 h after serum starvation (Fig. 3C, left) . HGF significantly increased the number of nuclear caspase-3-positive cells. It is noteworthy that DEVD-FMK (a caspase inhibitor) repressed a large part of the HGF-mediated increase in the number of apoptotic cells (Fig. 3C, right) . We next examined whether these findings would be reproducible in fibrotic lung-derived fibroblasts, using a primary culture system (25) . The cultured lung fibroblasts also expressed α-SMA and c-Met proteins (not shown) as revealed in situ ( Fig. 2A) . Of note, HGF enhanced apoptotic cell death, as evidenced by TUNEL staining (Fig. 3D) . In this primary culture, HGF-mediated apoptosis was repressed by DEVD-FMK, meaning involvement of caspase activation in HGF-mediated apoptosis. Since growth of the primary myofibroblasts was limited, we used myofibroblast-like MRC5 cells for further analysis of how HGF induces apoptosis in myofibroblasts.
MMP-dependent apoptosis in myofibroblasts
Interstitial FN is important for cell survival that depends on anchorage to ECM (26, 27) , while HGF enhances apoptotic cell death under FN-deficient conditions (28). Therefore, we focused on FN and MMP-2 and MMP-9, predominant proteases responsible for extracellular degradation of FN during progression of HGF-mediated apoptosis. In cultures of myofibroblast-like MRC-5 cells, HGF increased active MMP-2 and MMP-9 levels in the supernatants of myofibroblasts, whereas the increase in MMP-9 level by HGF was more potent than that seen in MMP-2 (Fig.  4A) . We next asked whether HGF-induced MMPs are involved in myofibroblast apoptosis. When recombinant MMP-2 and/or MMP-9 were added to myofibroblast-like MRC-5 cells, significant increases in TUNEL-positive cells were seen, and MMP-9 was more potent than MMP-2 to enhance apoptosis, at the concentration tested (50 µM) (Fig. 4B, left) . Inversely, addition of MMI270, a broad-spectrum inhibitor for MMPs, diminished HGF-mediated apoptosis by 75% (Fig. 4B, right) , hence strongly suggesting that MMPs play a critical role in apoptotic cell death of myofibroblast-like MRC5 cells promoted by HGF.
Roles of FN-related signals in apoptosis
The CCB domain in FN is a key bridge between integrins and FN (29). In our MRC5 model, anti-FN-CCB IgG (E2E) dose-dependently increased the number of apoptotic cells (Fig. 4C,  left) , meaning that the cell-substratum interaction mediated by FN-CCB is important for myofibroblast anchorage and survival. Thus, our attention was directed to the possibility that HGF alters the accumulation of this CCB domain: immunoblot analysis, using the E2E antibody, revealed that extracellular FN-CCB accumulation in cultures of myofibroblast-like MRC5 cells was reduced by treatment with HGF, while MMP inhibition with MMI270 restored such a suppressive effect by HGF (Fig. 4C, right) . These results suggest that HGF-induced MMPs are critical for breakdown of FN-CCB domain involved in cell survival. We then focused on intracellular FAK because FAK phosphorylation via FN-mediated signals is believed to be critical for cell survival (27). During the culture period of 96 h, total FAK expression in myofibroblast-like MRC5 cells, as evidenced by Western blot, was decreased by HGF (Fig. 4D) . Moreover, HGF inhibited FAK phosphorylation, whereas this effect was released when MMI270 was added together with HGF (Fig. 4D ). These findings suggest that the decrease in cellsubstratum interaction mediated by FN and FAK signals is involved in HGF-mediated apoptosis, being associated with the increased MMP activities by HGF. A previous study indicated that HGF inhibits apoptosis of cancer cells cultured in an anchorage-independent fashion (30). Thus, biological effects of HGF on apoptosis regulated by cell-substratum interaction seem to be different or bidirectional, depending on cell types, for example, nonneoplastic vs. neoplastic cells, or culture conditions. Perhaps, characteristics of tumor cells (such as resistance to anchorage-independent conditions or aberrant activation status of signal transduction molecules involved in cell-substratum interactions) may influence the apoptosis regulated by HGF.
Apoptotic effect of HGF on myofibroblasts in vivo
We returned to the animal model to determine whether 1) HGF has apoptotic effects on myofibroblastosis in vivo and 2) MMPs play a critical role during the apoptotic process, using the MMP-inhibitor, MMI270 (Fig. 5A) . HGF administrations increased active MMP-9 and MMP-1 (proteases for degradation of interstitial FN and collagens, respectively) levels in the BLM-treated lungs to more than a twofold level of the saline control, while MMI270 repressed the HGF-mediated increases in active MMP-1/-9 levels (Fig. 5B) . Together with the increase in MMP-9 levels, HGF increased the number of cells double-positive for TUNEL and α-SMA in the lung compared with findings in saline-injected controls (Fig. 5C ), suggesting that HGF stimulated apoptosis in myofibroblasts in fibrotic lungs. A combination of HGF plus MMI270 significantly suppressed HGF-mediated apoptotic effects on myofibroblasts (Fig. 5C, 5D ). Likewise, HGF reduced interstitial areas (occupied by FN-CCB, myofibroblasts, and collagens), but these antifibrotic effects of HGF were suppressed by the concomitant MMI270 administrations (Fig. 5D ). Consistently with histological evidence, the lung hydroxyproline level was reduced by HGF, whereas it increased in mice treated with HGF plus MMI270 over levels in mice treated with HGF alone (4W: 57.9±9.73 µg/mg vs. 23.8±6.09 µg/mg, P<0.05) (Fig. 5E ).
Together with these findings, HGF accelerated alveolar and endothelial repairs and all these events were associated with improved exercise activity (not shown).
DISCUSSION
Although it had been believed that tissue fibrosis is irreversible once a sclerotic lesion is established (1), there is now ample evidence showing that interstitial fibrosis can be reduced. In this process, myofibroblast apoptosis becomes evident especially around ECM-deficient areas (9, 10) . However, it remained unknown 1) which ligand(s) elicits myofibroblast cell death in fibrotic areas and 2) how myofibroblast apoptosis is linked with concomitant degradation of ECMs. Using mice and culture models of pulmonary fibrosis, we found that HGF elicits myofibroblast cell death concomitantly with the MMP inductions and ECM disappearance, and then morphological as well as functional repair is accelerated. Because graft donation for lung transplantation is difficult, medical treatments with a growth factor(s) may be more practical for recovery from lung fibrosis.
In the lung of bleomycin-treated mice, interstitial fibroblasts acquire the c-Met/HGF receptor after conversion to myofibroblasts, whereas ligand HGF enhanced myofibroblast apoptosis. For a variety of cells, HGF has anti-apoptotic action (31, 32) , whereas HGF has the potential to stimulate apoptotic cell death in some distinct types of cells, including transformed or neoplastic cells (33) , indicating that HGF biologically regulates cell survival in a cell type-dependent manner. However, mechanisms by which HGF enhances apoptosis have yet to be fully understood. In our murine model, myofibroblast apoptosis became evident when interstitial ECM levels were lowered by HGF. Inversely, inhibition of ECM disappearance by MMI270 led to suppression of myofibroblast cell death enhanced by HGF. Similar findings were reproducible in vitro, using myofibroblast-like MRC5 cells. Based on the current data, we emphasize that loss in the ECM anchor is a prerequisite for HGF to exert apoptotic effects on myofibroblasts.
Considering that not only myofibroblast depletion but also ECM disappearance is required for reversing fibrosis (9, 10) , such an apoptotic mechanism seems to be physiologically adaptable for these purposes.
To determine a critical site(s) among ECMs, we next focused on a FN-CCB domain, since this site is important for cell adhesion and survival, as shown elsewhere (29) and herein. Of note, HGF reduced CCB-accumulating levels of myofibroblasts in a reciprocal manner to an increase in MMP levels. Furthermore, HGF addition led to the loss in FAK phosphorylation in myofibroblasts, along with reduced accumulation levels of CCB domain. In this process, active caspase-3 becomes evident by HGF. Of note, HGF-mediated caspase-3 activation and apoptosis were both diminished when suppression of FAK phosphorylation was restored by MMP inhibition. Thus, possible cascades involved in HGF-induced apoptosis seem to include the following: 1) CCB domain (as a ligand of integrins) may be degraded by HGF-induced MMPs; 2) FAK phosphorylation is in turn suppressed; and 3) eventually, caspase systems are activated, resulting in DNA fragmentation. Perhaps, the loss in survival signals via FN/FAK may play a predominant role in onset of HGF-induced apoptosis in myofibroblasts presumably as if cells undergo "anoikis" (34) , apoptotic cell death induced by a loss of anchorage to the extracellular substrate.
Although activation of ECM-degradative pathways is noted during progression of lung fibrosis (35, 36) , it is still controversial whether induced MMPs are protective or pathogenic toward fibrosis. Based on the present data, we predict that HGF-induced MMPs may play a role to reduce fibrosis: lung active MMP-9/-1 levels increased when myofibroblast apoptosis and ECM disappearance were accelerated by HGF. Inversely, an MMP-inhibitor restored antifibrotic effects by HGF, associated with suppressed MMP-9/-1 activities. HGF is a potent inducer of MMPs in stromal cells (37, 38) , whereas endogenous HGF is critical to suppress lung fibrosis in BLM-treated mice (39) . Together, it is likely that HGF-recruited MMPs provide an intrinsic system to antagonize lung fibrogenesis: 1) MMP-9 induced by HGF may enhance myofibroblast cell death via destructing FN-CCB, and 2) HGF-induced MMP-1 may function as a collagenase to lessen lung consolidation (see Fig. 5B ). Since HGF production is impaired in advanced lung fibrosis (40) , supplement of HGF seems reasonable to promote myofibroblast apoptosis and ECM deletion. Given that MMI270 is a broad MMP inhibitor with undetermined specificity and its effect is not complete, we cannot exclude a possibility that MMP-independent pathways are involved in HGF-mediated apoptotic mechanisms.
It is important to discuss a cytokine network(s) in regulating a balance between myofibroblast apoptosis vs. its inhibition: inflammatory cytokines such as interleukin-1β (IL-1β) are important to elicit myofibroblast death (41) . IL-1β is a potent inducer of HGF expression (42) . Thus, IL-1β may be cooperating with HGF to induce myofibroblast apoptosis. TGF-β1 is a survival ligand for myofibroblasts (43) , whereas HGF inhibits active TGF-β1 production in myofibroblasts (37, 44) . Thus, HGF-mediated suppression of TGF-β1 activation may participate in apoptotic mechanism. Other antifibrotic mechanisms proposed in previous studies include 1) HGFmediated down-regulation of fibrogenic cytokines (i.e., TGF-β, platelet-derived growth factor [PDGF] and connective tissue growth factor [CTGF]) (45-47), 2) inhibition of myofibroblast overgrowth by HGF (24) , and 3) preventive effect of HGF on myofibroblast differentiation (48) . Furthermore, protection and repair of lung epithelial cells by HGF, as noted previously (15, 17, 20) and herein, would be involved in HGF-mediated antifbrotic mechanisms.
In this study, we identified HGF as a ligand, which is critical for inducing myofibroblast removal and ECM degradation in vivo. Overall, losses of interstitial components were replaced by parenchymal repairs, followed by improvement in clinical findings. Such therapeutic effects were reproduced in other fibrotic organs (45) (46) (47) , where myofibroblast-occupied areas were markedly reduced. Our study may provide a clue as to how regression (vs. progression) of fibrosis is molecularly regulated and how one can deal with cases of chronic organ failures. Changes in hydroxyproline levels in the BLM-treated lungs. The hydroxyproline levels were determined in a time course of pretreatment (0W) to endpoint (4W). In this endpoint, hydroxyprorile levels were compared among groups of saline vs. rh-HGF in BLM-untreated and in BLM-treated mice. Data are shown as mean ± SD (n=6). Statistical analysis: **P < 0.01 compared with the same time point of the control group. # P < 0.05 vs. pretreatment group (2W). An ANOVA test was used to compare the mean value, using statistical computer software (Start-View J 6.0). C) Representative microphotographs of myofibroblast hyperplasia, as detected by α-SMA-positive spindle-shaped cells. Bar graphs mean % of α-SMA-positive interstitial areas (excluding peri-bronchial areas) to total areas (mean±SD, n=6). For abbreviations, see text.
# P < 0.05 and ## P < 0.01 vs. 2W, **P < 0.01 vs. 4W. . HGF enhanced apoptosis in myofibroblast-like MRC5 cells at 96 h after serum removal, while DEVD-FMK repressed such apoptotic changes. Degrees of apoptosis were quantified by counting more than 1000 cells and expressed as TUNEL-positive %. D) Apoptotic effects of HGF toward fibrotic lung-derived myofibroblasts in a primary culture system. The myofibroblasts were isolated form mice treated with BLM for 2 wk (as same as for Fig. 2A ), based on a previous method (25) . The cells were cultured with or without HGF for 96 h under FBS-free conditions, and apoptotic effects were evaluated using TUNEL stainings. DEVD-FMK was used as same as for Fig. 3C . Protocol for MMP inhibition (with MMI270) in the HGF supplement toward BLM-treated mice. B) In vivo effect of MMI270 on active MMP-9 and MMP-1 levels in mouse lungs treated with BLM. Data are shown as a mean value ± SD (n=6). Statistical analysis: *P < 0.05 , **P < 0.01 vs. saline group, and # P < 0.05 vs. HGF group. C) Changes of the myofibroblast apoptosis in the BLM-treated lungs by HGF or HGF plus MMI270. The incidence of myofibroblast apoptosis was expressed as a ratio of double-positive cells in >1000 α-SMA-positive interstitial cells. D) Histochemical findings of myofibroblast apoptosis and interstitial fibrosis in the lungs. Top: Changes of interstitial FN-CCB deposition by HGF alone or HGF plus MMI270 (×260). Middle: Detection of apoptosis in interstitial myofibroblasts. The myofibroblasts were visualized as cytoplasmic red (i.e., α-SMA-positive) signals, while apoptosis was detected as nuclear brown signals (in an expanded frame) (×360). Bottom: Changes in lung fibrosis by HGF or combined MMP inhibition (type I collagen staining) (×200). E) Comparison of lung hydroxyproline levels among saline-, HGF-, and HGF plus MMI270-injected groups.
